ARTICLE | Preclinical News

Targeting RAS via surface proteins

January 25, 2018 11:47 PM UTC

In a paper published in eLife, researchers at the University of California San Francisco identified a new way to target Ras-mutant tumors via up-regulated extracellular antigens. The team showed antibodies against one of the antigens can be used as a component of cytotoxic or immunotherapeutic agents, suggesting a method could target cancer cells driven by intracellular Ras, long considered an undruggable target.

The study’s authors used mass spectrometry based-proteomics and RNA sequencing to compare the surface protein levels of two human epithelial cell lines with and without the oncogenic K-Ras (KRAS) G12V mutation and identified seven highly up-regulated single-pass transmembrane receptors induced by KRAS...